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Abstract
Background: Human Immuno-deficiency Virus (HIV) associated non-Hodgkin’s lymphoma (NHL) was a special group
of disease, which manifests distinct clinical features and prognosis as compared with NHLs in patients without HIV. We
performed this study to describe the clinical features of the disease and investigated the potential prognostic factors.
Methods: HIV-infected patients who were newly diagnosed with NHL were enrolled in this study. The selection of
anti-lymphoma treatment regimen was mainly dependent on the pathological subtypes of NHLs. Tumor response was
reviewed and classified according to the International Workshop Criteria.
Results: A total of 78 patients were enrolled, among whom, 42 (53.8%) were with Diffuse large B cell Lymphoma
(DLBCL), and 29 (37.2%) were with Burkitt lymphoma (BL). BL patients presented with higher risk features as compared
with DLBCL in terms of numbers of extranodal diseases (P = 0.004) and poor Eastern cooperative oncology group
(ECOG) score (P = 0.038). The estimated 2-year overall survival (OS) and progression free survival (PFS) rate was 74.3 ± 8.
1%, 28.9 ± 11.0%, and 54.2 ± 8.1%, 19.2 ± 7.5% for DLBCL and BL, respectively. In multivariate analysis, international
prognostic index (IPI) score was an independent prognostic factor for predicting both OS (OR = 2.172, 95% CI 1.579–2.
987, P < 0.001) and PFS (OR = 1.838, 95% CI 1.406–2.402, P < 0.001).
Conclusions: HIV associated NHLs represents a group of heterogeneous aggressive diseases with poor prognosis. IPI
parameters were still effective in predicting the prognosis of HIV associated NHLs.
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Background
Non-Hodgkin’s Lymphoma (NHL) is one of the most
common types of malignancies with high morbidity and
mortality in the patients who were infected by Human
Immune-deficiency Virus (HIV) [1]. Generally, HIV
associated NHLs present with more aggressive clinical be-
haviors as compared with general population, exemplified
with a huge tumor burden, more extranodal diseases, and
a tendency of involving genital system [2, 3]. Fortunately,
although the prognosis of HIV associated NHLs remains
very poor, with the introduction of combined antiretro-
viral therapy (cART) and high dose chemotherapy, a con-
siderable portion of the patients could be cured [4, 5].
The International Prognostic Index (IPI) [6], which in-
cludes age, Eastern Cooperative Oncology Group (ECOG)
performance status, Lactate Dehydrogenase (LDH) level,
Ann Arbor stage, and extranodal involvement, is used ex-
tensively for evaluating patients with aggressive lymph-
omas, especially for those with diffuse large B cell
lymphoma (DLBCL) and receive doxorubicin-containing
chemotherapy such as R-CHOP [7, 8]. Although its role
as prognostic factor in stratification of the NHL patients
in daily practice and clinical trial is well established in
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general population, its validity remains controversial in
HIV associated NHLs.
Another important issue is the complexity of the back-
ground of the HIV associated NHLs, such as more aggres-
sive phenotype, immune-deficiency status. What even
worse is that treatment factors (cART) also intervene the
clinical outcome and prognosis [9–11]. Chronic antigen
stimulation (HIV infection) could lead to a polyclonal B-
cell expansion and finally promotes the emergence of
monoclonal B cells. Both germinal center B cell-like
(GCB) active B cell subtype (ABC) could be observed in
HIV associated DLBCL. The frequency of double hit mu-
tation could be observed in around 20% in HIV patients
with NHLs [12–14]. Thus, a more comprehensive analysis
incorporating above mentioned factors is warranted to
give more precise stratification of HIV associated NHLs.
In China, with the increasing of incidence of HIV infec-
tion in recent years, acquired immunodeficiency syndrome
(AIDS) associated NHL became more and more frequently.
This subset of the patients might present distinct clinical
behavior and treatment outcome as compared with their
western counterpart. Hence, we performed this study to de-
scribe the clinical features and evaluate the potential prog-
nostic factors of the Chinese AIDS patients with NHLs.
Methods
Patients
The HIV-infected patients who were newly diagnosed
NHL were consecutively entered in this study from
Jan.2002 to May.2015 in Shanghai Public Health Clinical
Center. The subtypes of the lymphoma were defined ac-
cording to the WHO 2008 classification system.
Systemic evaluation of the patients including complete
blood cell count (CBC), biochemical parameters, LDH, viral
panel (HIV, HBV, and HCV etc.), CD4 cell count, bone
marrow and radiological examinations, was performed to
stage the disease and assess the general and disease status.
Anti-lymphoma treatment
Sixty-four out of 78 patients received anti-lymphoma treat-
ment, and the regimen for the first line chemotherapy was
mainly dependent on the pathological subtypes of lymph-
omas. For BL and PBL, Hyper-CVAD A (Cyclophospha-
mide [CTX] 300 mg/m2 Q12h × 6, D1-3, Dexamethasone
[DEX] 40 mg/d, D1-4, D11-14, Vincristine [VCR] 1.4 mg/
m2, D4, D11, Adriamycin [ADR] 50 mg/m2, D4) and B
regimen (Methotrexate 1 g/m2, D1, Ara-C 2 g/m2 Q12h,
D2-3) were given alternatively to the patients. For DLBCL,
CHOP regimen (CTX 750 mg/m2, D1, ADR 50 mg/m2,
D1, VCR 1.4 mg/m2, D1, Prednisone 60 mg/m2, D1) was
initially designed for the patients, initiated from Dec.2014,
to enhance the efficacy of young high risk patients (age <
60 years, IPI > 1). DA-EPOCH (Etopside 50 mg/m2 D1-4,
VCR 0.4 mg/m2 D1-4, ADR 10 mg/m2 D1-4, all above
continuous for 24 h, CTX 750 mg/m2 D5, DEX 40 mg D1-
5) was also given to this subgroup of the patients [15]. The
patients with FL and IBL received CHOP regimen the
same as those with DLBCL. The detailed treatment regi-
men was depicted in Additional file 1: Table S1. No irradi-
ation therapy was given concurrently during the treatment.
Rituximab 375 mg/m2 was designed to give to the pa-
tients with a suitable CD4 cell count (>50 cells/μl) to
prevent the deep suppression of both B and T cell im-
munity. Since rituximab usage is not covered by medical
insurance in most provinces in China, the application of
treatment with rituximab also depended on patients’








Median 44 54 48
Range 24–73 25–73 33–74
P = 0.151
Gender (%)
Male 37 (88.1) 27 (93.1) 5 (83.3)
Female 5 (11.9) 2 (6.9) 1 (6.7)
P = 0.692
Ann Arbor stage (%)
I, II 23 (54.8) 10 (34.5) 3 (50.0)
III, IV 19 (45.2) 19 (65.5) 3 (50.0)
P = 0.146
Extranodal diseases (%)
0,1 33 (78.6) 15 (51.7) 4 (66.7)
> 1 9 (21.4) 14 (48.3) 2 (33.3)
P = 0.004
LDH
Median 334 373 283
Range 139–6016 178–5009 182–739
P = 0.257
ECOG score (%)
0,1 18 (42.9) 5 (17.2) 3 (50.0)
> 1 24 (57.1) 24 (82.8) 3 (50.0)
P = 0.038
IPI (%)
0,1 16 (38.1) 5 (17.2) 3 (50.0)
> 1 26 (61.9) 24 (82.8) 3 (50.0)
P = 0.069
CD4 cell count
Median 106 108 31
Range 4–483 1–549 3–69
P = 0.526
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willing. Fifty patients had a CD4 count greater than 50
(2 with PBL without CD20 expression), and 20 patients
(40%) received rituximab.
The first line treatment regimen was discontinued if
patients experienced any severe adverse event or lymph-
oma progressing. The initiation of the second line or sal-
vage treatment regimen for relapsed and refractory
patients was dependent on the decision of the physicians
according to the condition of the patients.
Anti-HIV treatment
ART was given immediately after the diagnosis of HIV with
the exception of 5 patients due to rapid progression of
lymphoma [16]. They were receiving either a combination of
2 nucleoside reverse transcriptase inhibitors with a protease
inhibitor (n= 1) or with a non-nucleoside reverse transcript-
ase inhibitor (n= 70), or with an integrase inhibitor (n= 2).
Response assessment
Evaluation of the efficacy was performed one month
after completion of all the treatment. Thoracic, abdom-
inal, and pelvic computed tomography scans were
performed even if those areas were not initially affected
[17, 18]. Interim staging was performed after completion
of four cycles of treatment for DLBCL and FL patients.
For BL and IBL patients, these evaluations were per-
formed every 2 cycles. Tumor response was based on
radiographic review and classified as complete response
(CR), partial response (PR), overall response (OR, CR +
PR), stable disease (SD), or progressive disease (PD) ac-
cording to the International Workshop Criteria [19].
Statistical analysis
Fisher’s Exact P test and one way ANOVA test were used
to compare the clinical parameters in different subtypes of
lymphoma. All patients entered into the study were
followed up. Overall survival (OS) was measured from the
date of disease diagnosis to death (failure) or alive at last
follow-up (censored). Progression free survival (PFS) was
defined as time from disease diagnosis to treatment failure
such as relapse, progressive disease, any new anti-
lymphoma treatment, and death of any reasons, or alive in
CR at last follow-up (censored). Kaplan-Meier analysis was
used to calculate the distribution of OS and PFS. Binary lo-
gistic regression was used for the multivariate analysis of
prognostic parameters for response, while Cox model was
used to identify prognostic variables for OS and PFS. A
limited backward selection procedure was used to exclude
redundant or unnecessary variants. To provide quantitative
information on the relevance of results, 95% confidence in-
tervals (95% CIs) of odds ratios (ORs) was calculated. All
above statistical procedures were performed with the SPSS
statistical software package, version 16.0.
Results
Patient characteristics
A total of 78 patients were enrolled, among whom, 42
(53.8%) were with DLBCL, 29 (37.2%) were with Burkitt
lymphoma (BL), 5 (6.4%) were with plasmablastic
lymphoma (PBL) and 1 (1.3%) was with follicular
lymphoma (FL) and angioimmunoblastic lymphoma
(IBL), respectively. The median age of the patients was
48 (24–74). A strong tendency of male patients was ob-
served (89.7% vs. 10.3%). The clinical characteristics of
the patients were shown in Table 1. The BL patients
Fig. 1 Kaplan-Meier curves for overall survival (OS) and progression free survival (PFS) of treated patients. a OS, (b) PFS
Table 2 Baseline characteristics of HIV condition of the patients
Characteristics
AIDS before lymphoma diagnosis (n, %) 25 (33)
ART at lymphoma diagnosis (n, %) 17 (22)
ART exposure from lymphoma diagnosis (months) 12 (1–84)
Patients with CD4 count <200 cells/uL (n, %) 59 (75)
HIV RNA < 40 copies/ml at lymphoma diagnosis (n, %) 11 (14)
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presented with higher risk features as compared with
DLBCL patients in terms of numbers of extranodal dis-
ease (P = 0.004) and poor ECOG score (P = 0.038), while
age (P = 0.151), gender (P = 0.692) and CD4 cell count
(P = 0.526) were distributed equally in the two groups.
33% (25/78) of the patients was confirmed to be infected
with HIV before lymphoma diagnosis. 22% (17/78) of them
received ART with a median treatment exposure of
12 months before the diagnosis of lymphoma, whereas 78%
(61/78) of the patients were ART-naïve. 67% (53/78) of the
patients were simultaneously diagnosed of lymphoma and
HIV. Notably, 14% (11/78) of the patients had a plasma
HIV-1 RNA viral load below 40 copies/ml at the time of
lymphoma diagnosis. Table 2 summarized the baseline
characteristics of these patients.
Treatment response
Among 35 DLBCL patients, 22 (62.9%) and 26 patients
(74.3%) achieved CR and OR, respectively. For 23 patients
with BL, 5 (21.7%) achieved CR while 8 patients (34.8%)
achieved OR. One patient with FL achieved PR. None of
the patients with PBL and IBL obtained any response.
Further prognostic analysis for CR induction was per-
formed in 58 patients with DLBCL or BL after anti-
Fig. 2 Univariate analysis of potential prognostic clinical factors. a, b Ann Arbor stage for OS and PFS. c, d Extranodal Diseases for OS and PFS
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lymphoma treatment. As shown in Additional file 1: Table
S2, in univariate analysis, DLBCL has significant higher CR
rate than BL (P = 0.003). Ann Arbor stage (P < 0.001),
number of extranodal disease (P = 0.001), ECOG perform-
ance status (P = 0.001), LDH (P = 0.008) and IPI (P < 0.001)
were proved to be significantly associated the CR
induction results.
IPI score and pathological types were entered into
multivariate logistic regression analysis. It was proved that
pathological types (DLBCL vs. BL, P = 0.038, OR = 0.240,
95% CI 0.063–0.925) and IPI score (P < 0.001, OR = 0.371,
95% CI 0.229–0.601) were independent prognostic factors
of CR (Table 4).
Survival analysis
Among 64 patients who received anti-lymphoma treat-
ment, the median follow up time was 13.5 months due
to the poor prognosis of the patients. The estimated
2 year OS and PFS rate were 74.3 ± 8.1%, 28.9 ± 11.0%,
20.0 ± 17.9%, and 54.2 ± 8.1%, 19.2 ± 7.5%, and 0% for
Fig. 3 The usefulness of ECOG and IPI in predicting the prognosis of patients. a, b ECOG performance status for OS and PFS. c, d IPI for OS and PFS
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DLBCL, BL and PBL + IBL, respectively (Fig. 1). One FL
patient who achieved PR relapsed after 1 year.
Since a survival plateau could be observed in DLBCL
and BL patients (Fig. 1), further prognostic analysis was
performed in a group combining the two subsets of the
patients. As shown in Figs. 2 and 3, Ann Arbor stage (I,
II vs. III, IV), number of extranodal diseases (0, 1 vs. >
1), ECOG performance status (0,1 vs. > 1), and IPI score
(0,1 vs. > 1) were all significantly associated the survival
(OS and PFS) of the patients. LDH as continuous vari-
able, could predict OS (HR = 1.000, 95% CI 1.000–1.001,
P = 0.001) and PFS (HR = 1.000, 95% CI 1.000–1.001,
P = 0.002), while CD4 cell count at diagnosis was not
associated with the treatment outcome (OS: HR =
1.000, 95% CI 0.996–1.003, P = 0.824; PFS: HR = 0.998,
95% CI 0.992–1.005, P = 0.733). The estimated 2-year
OS and PFS rates were shown in Table 3.
In multivariate analysis, only IPI score was the in-
dependent prognostic factor for predicting both OS
(OR = 2.172, 95% CI 1.579–2.987, P < 0.001) and PFS
(OR = 1.838, 95% CI 1.406–2.402, P < 0.001) (Table 4).
Discussion
HIV associated NHL represents a type of aggressive ma-
lignancies. Although intensive chemotherapy was given,
the prognosis of the disease remained very poor. It was
controversial whether some important prognostic factors
in HIV negative counterpart such as IPI could still work
in this special group of the patients [20]. In this study,
we included a cohort of 78 patients to analyze the char-
acteristics of AIDS associated NHL and to evaluate the
prognostic factors of the disease.
Very similar to the normal HIV negative population,
the most common subtype of lymphoma observed in
HIV-infected patients was also DLBCL (42/78, 53.8%)
[21]. As an important trigger of HIV to activate c-myc,
BL was the second common pathologic subtype of the
lymphoma (29/78, 37.2%) among this population. Com-
pared to NHL in general population, AIDS patients with
NHL presents with a more aggressive features including
advanced Ann Arbor stage, significantly elevated LDH,
and poor ECOG performance status, and a high IPI
score eventually [2]. Of note, BL patients presented with
even higher risk features while compared with those
with DLBCL [22]. According to our data, BL patients
manifested with the feature of more extranodal diseases
(P = 0.004) but poorer ECOG scores (P = 0.038).
In this study, it was observed that the Chinese NHL pa-
tients presented with the characteristics of very low rate of
ART exposure prior to the lymphoma diagnosis. Its nega-
tive impact on the anti-tumor treatment outcome could
not be excluded. The severe immunosuppression status as
well as the more aggressive disease phenotypes of these pa-
tients all strongly challenged the health care providers. One
of the main reasons for the late ART initiation is that most
of AIDS patients in China are from low income class, or so
called “grass roots”, who are often less educated, single or
separated from their family to work outside to strive. Al-
though Chinese government have made great efforts to
provide the basic education of AIDS, making the free ART
publicly available, especially to this population, it seemed
that a long way still needs to be run to popularize contem-
porary knowledge of HIV in such a large country with a
huge population. The ignorance of the HIV infection of the
patients and the prejudice from their family members
should be firstly diminished. In this study, most of the
patients came to the hospital not for suspicion of HIV
infection, but for the complications, including but not
limited to fever, unexplained symptoms and signs, or even
hematological events like tumor or pancytopenia.
AIDS patients with DLBCL or BL could still achieve a
survival plateau. However, it seemed that this plateau is
significantly lower than that of the HIV negative coun-
terpart, especially for BL patients [23]. In this study, the
Table 3 The 2 year estimated OS and PFS rate in different
subgroups
OS (%) PFS (%)
Ann Arbor stage
I, II 88.6 ± 6.3 68.6 ± 8.3
III, IV 13.0 ± 10.3 8.4 ± 6.7
Extranodal diseases
0, 1 71.7 ± 7.8 54.5 ± 7.4
> 1 10.3 ± 9.5 0
ECOG score
0, 1 90.2 ± 6.6 73.9 ± 9.2
> 1 51.4 ± 9.0 20.1 ± 6.7
IPI score
0, 1 95.0 ± 4.9 80.4 ± 8.8
> 1 49.6 ± 8.8 19.9 ± 6.4
Table 4 Multivariate analysis of potential prognostic factors for the patients
Variables CR OS PFS
P OR (95% CI) P OR (95% CI) P OR (95% CI)
IPI score <0.001 0.371 (0.229–0.601) <0.001 2.172 (1.579–2.987) <0.001 1.838 (1.406–2.402)
Pathology subtype
(DLBCL vs. BL)
0.038 0.240 (0.063–0.925) NS – NS –
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2-year OS and PFS rates for DLBCL and BL were 74.3 ±
8.1%, 28.9 ± 11.0%, and 54.2 ± 8.1%, 19.2 ± 7.5%, respect-
ively. High dose chemotherapy other than Hyper-CVAD
A and B using the strategy including more anthracyclin
(it was observed that most of BL patients progressed
while received B regimen), might be designed. As for
DLBCL, CHOP is not enough for the HIV-infected pa-
tients. An escalated regimen such as DA-EPOCH or
CHOP-E should be considered for further clinical trial.
Various prognostic parameters have been used for pre-
dicting the treatment outcome of NHL [7, 11, 24]. Among
them, the IPI is probably the most commonly used one
[25]. Based on IPI, various systems such as FLIPI were de-
signed for some special subtypes of lymphoma [24]. In this
study, we have examined the efficacy of IPI parameters in
HIV associated NHL (mostly BL and DLBCL). It was en-
couraging to prove that IPI parameters still worked in such
kind of the patients, almost all the IPI parameters were use-
ful in univariate analysis, and IPI was the independent
prognostic factor for predicting both OS and PFS. Interest-
ingly, the initial CD4 count before treatment was not associ-
ated with the treatment outcome of lymphoma in terms of
CR rate, OS or PFS. It was traditionally believed that a low
CD4 cell count was associated with death, which was proved
in two large studies in pre-cART and early cART eras [26].
We believed that with the wide application of cART treat-
ment, viral load and other related factors were abrogated.
Conclusion
HIV associated NHLs represents a group of heterogeneous
aggressive diseases with poor prognosis. Current anti-
lymphoma treatment should be improved in this special
group of patients in future clinical practice. IPI still works in
the HIV-infected NHL patients in predicting the prognosis
during the cART era. However, this study was a retrospect-
ive one and the treatment outcome of the patients, espe-
cially for BL, need to be further monitored. And the
potential usefulness of existing clinical prognostic factors in
AIDS patients should be further addressed in future studies.
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